BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 19470932)

  • 1. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.
    Kemeny NE; Melendez FD; Capanu M; Paty PB; Fong Y; Schwartz LH; Jarnagin WR; Patel D; D'Angelica M
    J Clin Oncol; 2009 Jul; 27(21):3465-71. PubMed ID: 19470932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y
    J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
    Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Gonen M; Stockman J; Blumgart L; Sperber D; Hummer A; Fong Y
    J Clin Oncol; 2003 Sep; 21(17):3303-9. PubMed ID: 12947066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
    Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
    J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.
    Gallagher DJ; Capanu M; Raggio G; Kemeny N
    Ann Oncol; 2007 Dec; 18(12):1995-9. PubMed ID: 17962209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer.
    House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI
    Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer.
    Chen Y; Wang X; Yan Z; Wang J; Luo J; Liu Q
    Onkologie; 2012; 35(9):480-4. PubMed ID: 23007144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer.
    Kemeny N; Gonen M; Sullivan D; Schwartz L; Benedetti F; Saltz L; Stockman J; Fong Y; Jarnagin W; Bertino J; Tong W; Paty P
    J Clin Oncol; 2001 May; 19(10):2687-95. PubMed ID: 11352961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
    Li C; Gu Y; Zhao M; Yuan Y; Wang F; Wang Z; Li W; Luo H; Chen C; Chen G; Ding P; Wu X; Lu Z; Pan Z; Xu R; He Y; Wan D; Li Y
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1079-87. PubMed ID: 25217393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
    Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
    Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
    Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study.
    Dhir M; Jones HL; Shuai Y; Clifford AK; Perkins S; Steve J; Hogg ME; Choudry MH; Pingpank JF; Holtzman MP; Zeh HJ; Bahary N; Bartlett DL; Zureikat AH
    Ann Surg Oncol; 2017 Jan; 24(1):150-158. PubMed ID: 27431415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
    Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
    Power DG; Kemeny NE
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):251-64. PubMed ID: 20970353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D
    BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
    Kemeny N; Capanu M; D'Angelica M; Jarnagin W; Haviland D; Dematteo R; Fong Y
    Ann Oncol; 2009 Jul; 20(7):1236-41. PubMed ID: 19233901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66.
    Alberts SR; Roh MS; Mahoney MR; O'Connell MJ; Nagorney DM; Wagman L; Smyrk TC; Weiland TL; Lai LL; Schwarz RE; Molina R; Dentchev T; Bolton JS
    J Clin Oncol; 2010 Feb; 28(5):853-8. PubMed ID: 20048179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.
    Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V
    BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.